tsh biopharmoration Ltd (8432) - Cash Flow Conversion Efficiency
Based on the latest financial reports, tsh biopharmoration Ltd (8432) has a cash flow conversion efficiency ratio of 0.027x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$42.55 Million ≈ $1.34 Million USD) by net assets (NT$1.58 Billion ≈ $49.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is tsh biopharmoration Ltd's balance sheet to measure how much of total assets are equity-financed.
tsh biopharmoration Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how tsh biopharmoration Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is tsh biopharmoration Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
tsh biopharmoration Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of tsh biopharmoration Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samart Telcoms Public Company Limited
BK:SAMTEL
|
0.208x |
|
Golan Plastic
TA:GLPL
|
0.112x |
|
Shandong Zhonglu Oceanic Fisheries Co Ltd
SHE:200992
|
-0.021x |
|
Bound and Beyond PCL
BK:BEYOND-R
|
N/A |
|
PW Consolidated Bhd
KLSE:7134
|
0.093x |
|
Atlantic International Corp. Common Stock
NASDAQ:ATLN
|
0.255x |
|
Safety Shot Inc
NASDAQ:SHOT
|
-0.072x |
|
Pulmonx Corp
NASDAQ:LUNG
|
-0.221x |
Annual Cash Flow Conversion Efficiency for tsh biopharmoration Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of tsh biopharmoration Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is tsh biopharmoration Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.62 Billion ≈ $51.13 Million |
NT$183.77 Million ≈ $5.79 Million |
0.113x | +323.28% |
| 2023-12-31 | NT$1.27 Billion ≈ $39.89 Million |
NT$33.87 Million ≈ $1.07 Million |
0.027x | -5.57% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.21 Million |
NT$34.35 Million ≈ $1.08 Million |
0.028x | -55.32% |
| 2021-12-31 | NT$1.08 Billion ≈ $34.14 Million |
NT$68.71 Million ≈ $2.16 Million |
0.063x | +515.07% |
| 2020-12-31 | NT$1.13 Billion ≈ $35.49 Million |
NT$11.61 Million ≈ $365.81K |
0.010x | -86.92% |
| 2019-12-31 | NT$1.12 Billion ≈ $35.44 Million |
NT$88.65 Million ≈ $2.79 Million |
0.079x | +41.06% |
| 2018-12-31 | NT$1.12 Billion ≈ $35.31 Million |
NT$62.62 Million ≈ $1.97 Million |
0.056x | -21.05% |
| 2017-12-31 | NT$1.15 Billion ≈ $36.12 Million |
NT$81.13 Million ≈ $2.56 Million |
0.071x | -- |
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more